Park Ha Biological Technology Co., Ltd. (BYAH) completes $1.8M private placement
Rhea-AI Filing Summary
Park Ha Biological Technology Co., Ltd. completed a Regulation S private placement with non-U.S. investors on August 3, 2026. The company issued 10,000,000 Class A ordinary shares, par value US$0.001, together with warrants to purchase up to 2,000,000 additional Class A shares, at a purchase price of US$0.18 per share and accompanying warrant, generating approximately US$1,800,000 in gross proceeds before expenses.
The warrants are immediately exercisable, carry a five-year term from issuance, and have an exercise price of US$0.18 per warrant share. The warrant terms state that the exercise price and warrant share count will not be adjusted for future share dividends, splits, combinations, recapitalizations or similar transactions. The securities were sold in offshore transactions to non-U.S. persons under Regulation S and are subject to transfer restrictions during the applicable distribution compliance period. The company plans to use the net proceeds for general working capital and corporate purposes.
Positive
- None.
Negative
- None.
Key Figures
Class A shares issued: 10,000,000 shares
Warrants issued: 2,000,000 shares
Unit purchase price: US$0.18 per Class A share and accompanying warrant
+3 more
6 metrics
Class A shares issued
10,000,000 shares
Aggregate Class A ordinary shares sold in the private placement
Warrants issued
2,000,000 shares
Maximum Class A ordinary shares issuable upon warrant exercise
Unit purchase price
US$0.18 per Class A share and accompanying warrant
Price paid by investors for each share plus accompanying warrant
Gross proceeds
approximately US$1,800,000
Aggregate gross proceeds to the company from the private placement
Warrant exercise price
US$0.18 per warrant share
Price at which each warrant share may be purchased
Warrant term
five years
Duration of the warrants from the date of issuance
Key Terms
Regulation S, distribution compliance period, Securities Purchase Agreement, Warrants, +1 more
5 terms
Regulation S regulatory
"offered and sold in offshore transactions to non-U.S. persons in reliance upon Regulation S"
Regulation S is a set of rules that allows companies to sell securities (like shares or bonds) to investors outside the United States without having to follow all U.S. securities laws. It matters because it makes it easier for companies to raise money from international investors while still complying with U.S. regulations.
distribution compliance period regulatory
"During the applicable distribution compliance period under Regulation S, the securities may not be offered"
Securities Purchase Agreement financial
"entered into a securities purchase agreement with certain non-U.S. investors"
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
Warrants financial
"together with warrants to purchase up to an aggregate of 2,000,000 Class A Ordinary Shares"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
gross proceeds financial
"resulting in aggregate gross proceeds to the Company of approximately US$1,800,000"
The total amount of cash a company receives from a financing event or sale before any fees, expenses, taxes or deductions are taken out. Investors watch gross proceeds because it shows the raw scale of new capital being raised—think of it as the paycheck amount before withholdings—which helps assess how much funding is available for operations, growth, debt payoff or how much shareholder dilution might occur once costs are removed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What transaction did Park Ha Biological (BYAH) report in August 2026?
Park Ha Biological (BYAH) reported completing a Regulation S private placement on August 3, 2026. It issued Class A ordinary shares and warrants to non-U.S. investors, raising approximately US$1,800,000 in gross proceeds before offering expenses.
How much capital did Park Ha Biological (BYAH) raise and who were the investors?
Park Ha Biological (BYAH) raised approximately US$1,800,000 in gross proceeds. The securities were sold to certain non-U.S. investors in offshore transactions, relying on Regulation S under the Securities Act for the offering exemption.
What are the key terms of the Park Ha Biological (BYAH) warrants?
The warrants are immediately exercisable, have a five-year term from issuance, and carry an exercise price of US$0.18 per warrant share. The exercise price and warrant share number will not be adjusted for share dividends, splits, combinations, or similar transactions.
How will Park Ha Biological (BYAH) use the proceeds from the private placement?
Park Ha Biological (BYAH) intends to use the net proceeds from the private placement for general working capital and corporate purposes. This includes funding ongoing operations and broader corporate needs, rather than being earmarked for a specific project or acquisition.
Under what exemption was the BYAH offering conducted and what are the transfer restrictions?
The offering relied on Regulation S, with securities sold in offshore transactions to non-U.S. persons. The securities are unregistered in the U.S. and, during the distribution compliance period, cannot be transferred to U.S. persons absent registration or a valid exemption.